Characteristics of tianeptine effects reported to a poison control center: a growing threat to public health
- 18 June 2020
- journal article
- research article
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 59 (2) , 152-157
Abstract
Background: Tianeptine is an antidepressant structurally similar to tricyclic antidepressants which is approved abroad but is currently a drug of abuse in the United States since at least 2000. In 2019, our poison center experienced an increase in calls relating to this xenobiotic. The goal of this report is to describe the characteristics of acute tianeptine intoxication and withdrawal. Methods: All calls to a statewide poison center regarding tianeptine were reviewed from January 1, 2015 to March 15, 2020. Cases were identified using the American Association of Poison Control Centers’ substance code for “other types of tricyclic antidepressants.” Cases were excluded if they did not involve tianeptine. Date of call, patient demographics, symptoms, cardiac intervals if available, and disposition were recorded. Results: Eighty-four cases of atypical tricyclic antidepressants were identified in the study period. Forty-eight cases involving tianeptine met inclusion criteria and were reviewed. Of these, 37 (77%) occurred from May 2019 to March 2020. Twenty-seven (56%) required medical admission including 17 cases (35%) that were managed in an intensive care unit. Seventeen of the 48 cases resulted from acute tianeptine intoxication. Lethargy was the most common presentation, but some patients also presented with agitation. Thirty-one (65%) of the cases resulted from tianeptine withdrawal, which usually exhibited agitation, anxiety, gastrointestinal distress. Naloxone was used in 4 cases (24%) of the acute intoxication cohort and benzodiazepines were frequently used both in acutely intoxicated patients and in patients experiencing tianeptine withdrawal. No patients in either cohort had cardiac conduction disturbances. Conclusion: Our center observed a dramatic rise in tianeptine toxicity, particularly in patients experiencing withdrawal symptoms, beginning in May 2019. More than half of the cases required medical admission including a third who were treated in the intensive care unit. Health care practitioners should be increasingly aware of this xenobiotic as usage may be on the rise.Keywords
This publication has 11 references indexed in Scilit:
- North American Congress of Clinical Toxicology (NACCT) Abstracts 2019Clinical Toxicology, 2019
- The STROBE guidelinesSaudi Journal of Anaesthesia, 2019
- Tianeptine Abuse and Dependence: Case Report and Literature ReviewPsychosomatics, 2018
- Characteristics of Tianeptine Exposures Reported to the National Poison Data System — United States, 2000–2017MMWR. Morbidity and Mortality Weekly Report, 2018
- Poison control center experience with tianeptine: an unregulated pharmaceutical product with potential for abuseClinical Toxicology, 2018
- Case Reports of Fatalities Involving Tianeptine in the United StatesJournal of Analytical Toxicology, 2018
- The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonistTranslational Psychiatry, 2014
- Risk Management in Tianeptine Abuse in Turkey: A National ExperienceKlinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology, 2013
- Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of DepressionRecent Patents on CNS Drug Discovery, 2006
- Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortexEuropean Journal of Pharmacology, 1993